VolitionRx (NYSE:VNRX – Get Free Report) was upgraded by equities research analysts at Jones Trading to a “strong-buy” rating in a research note issued on Tuesday, Marketbeat.com reports. The firm presently has a $3.00 target price on the stock. Jones Trading’s price objective indicates a potential upside of 434.95% from the company’s current price.
Other equities analysts have also recently issued research reports about the company. Wall Street Zen began coverage on VolitionRx in a report on Thursday, May 15th. They set a “sell” rating on the stock. D. Boral Capital reissued a “buy” rating and set a $5.00 price objective on shares of VolitionRx in a research note on Wednesday, April 30th. Finally, HC Wainwright started coverage on shares of VolitionRx in a research note on Tuesday, April 8th. They issued a “buy” rating and a $2.50 target price for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $3.50.
Get Our Latest Report on VolitionRx
VolitionRx Stock Up 0.7%
Insiders Place Their Bets
In related news, CEO Cameron John Reynolds purchased 181,818 shares of VolitionRx stock in a transaction dated Wednesday, March 26th. The stock was bought at an average price of $0.55 per share, for a total transaction of $99,999.90. Following the completion of the acquisition, the chief executive officer now directly owns 2,299,222 shares of the company’s stock, valued at $1,264,572.10. This represents a 8.59% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders acquired 271,818 shares of company stock worth $141,100 over the last ninety days. 10.40% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On VolitionRx
Several institutional investors have recently added to or reduced their stakes in the stock. Two Sigma Securities LLC bought a new position in VolitionRx during the 4th quarter worth about $29,000. Northern Trust Corp boosted its position in shares of VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after buying an additional 28,579 shares during the period. Lagoda Investment Management L.P. grew its holdings in shares of VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after buying an additional 1,481,000 shares in the last quarter. Finally, Millennium Management LLC bought a new position in shares of VolitionRx during the fourth quarter worth about $36,000. 8.09% of the stock is owned by institutional investors.
About VolitionRx
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Read More
- Five stocks we like better than VolitionRx
- Best Aerospace Stocks Investing
- Will Warner Bros. Discovery’s Split Produce Double the Upside?
- 3 Dividend Kings To Consider
- Is a Summer Slowdown Ahead for Microsoft Stock?
- Breakout Stocks: What They Are and How to Identify Them
- D-Wave Is Soaring—But Is ETF Diversification the Better Strategy?
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.